New antidepressants: Use in high-risk patients

A. S. Hale; B. E. Leonard; P. E. Stokes; J. F. Greden; G. D. Tollefson; A. C. Altamura

New antidepressants: Use in high-risk patients

A. S. Hale, B. E. Leonard, P. E. Stokes, J. F. Greden, G. D. Tollefson, A. C. Altamura

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.

Original language	English
Pages (from-to)	61-70
Number of pages	10
Journal	Journal of Clinical Psychiatry
Volume	54
Issue number	8 SUPPL.
Publication status	Published - 1993

ASJC Scopus subject areas

Psychiatry and Mental health
Clinical Psychology

Cite this

@article{2df1e81ce7944551a495ec427869eb24,

title = "New antidepressants: Use in high-risk patients",

abstract = "This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.",

author = "Hale, {A. S.} and Leonard, {B. E.} and Stokes, {P. E.} and Greden, {J. F.} and Tollefson, {G. D.} and Altamura, {A. C.}",

year = "1993",

language = "English",

volume = "54",

pages = "61--70",

journal = "Journal of Clinical Psychiatry",

issn = "0160-6689",

publisher = "Physicians Postgraduate Press Inc.",

number = "8 SUPPL.",

}

TY - JOUR

T1 - New antidepressants

T2 - Use in high-risk patients

AU - Hale, A. S.

AU - Leonard, B. E.

AU - Stokes, P. E.

AU - Greden, J. F.

AU - Tollefson, G. D.

AU - Altamura, A. C.

PY - 1993

Y1 - 1993

N2 - This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.

AB - This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.

UR - http://www.scopus.com/inward/record.url?scp=0027292331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027292331&partnerID=8YFLogxK

M3 - Article

C2 - 8253707

AN - SCOPUS:0027292331

VL - 54

SP - 61

EP - 70

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8 SUPPL.

ER -

New antidepressants: Use in high-risk patients

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this